Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) Infection
Status:
Completed
Trial end date:
2018-02-07
Target enrollment:
Participant gender:
Summary
The primary objectives of this study are to evaluate the efficacy, safety, and tolerability
of treatment with sofosbuvir/velpatasvir (SOF/VEL) fixed-dose combination (FDC) for 12 weeks
in adults with chronic hepatitis C virus (HCV) infection.
Phase:
Phase 3
Details
Lead Sponsor:
Gilead Sciences
Treatments:
Sofosbuvir Sofosbuvir-velpatasvir drug combination Velpatasvir